SCHEMBL608332

SCHEMBL608332

CC(=O)c1cnc(-c2ccc(Cl)cc2)s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.69
MAPT P10636 7/20 0.69
RAB9A P51151 9/20 0.68
NPC1 O15118 8/20 0.68
POLB P06746 4/20 0.68
PPARG P37231 2/20 0.64
NCOA2 Q15596 2/20 0.64
NCOA1 Q15788 2/20 0.64
NCOA3 Q9Y6Q9 2/20 0.64
NFKB1 P19838 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
ALDH1A1 P00352 8/20 0.62
HPGD P15428 1/20 0.61
CYP1A2 P05177 2/20 0.60
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
KDM4E B2RXH2 3/20 0.56
LMNA P02545 1/20 0.56
CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1193921 0.85 SMN1; SMN2 (0.71) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL14814199 0.83 PTPN11 (0.58) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL6604867 0.83 SMN1; SMN2 (0.69) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL850828 0.83 NPC1 (0.68) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL27807991 0.83 MAPT (0.64) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL13788324 0.81 CDC7 (0.66) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL12563592 0.80 HDAC1 (0.52) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL8345238 0.79 CDC7 (0.75) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL31301632 0.79 SMN1; SMN2 (0.61) SMN1; SMN2MAPTRAB9ANPC1POLB
SCHEMBL23579076 0.78 CDC7 (0.55) SMN1; SMN2MAPTRAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188294-B1 TRICYCLIC BRIDGED CYCLOPENTANEDIONE DERIVATIVES AS HERBICIDES SYNGENTA LTD (GB) 2015-03-18 EP disclosed
US-8956999-B2 Herbicides SYNGENTA LIMITED (GB) 2015-02-17 US disclosed
EP-2176222-B1 NOVEL HERBICIDES SYNGENTA LTD (GB) 2014-11-05 EP disclosed
US-8598365-B2 Herbicides SYNGENTA LIMITED (GB) 2013-12-03 US disclosed
EP-2173727-B1 NOVEL HERBICIDES SYNGENTA LTD (GB) 2013-11-06 EP disclosed
US-8541594-B2 2013-09-24 US disclosed
US-8530667-B2 Herbicides SYNGENTA LIMITED (GB) 2013-09-10 US disclosed
US-20120040826-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2012-02-16 US disclosed
US-20100298140-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2010-11-25 US disclosed
US-20100279868-A1 NOVEL HERBICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-11-04 US disclosed
EP-2188294-A2 TRICYCLIC BRIDGED CYCLOPENTANEDIONE DERIVATIVES AS HERBICIDES Syngenta Limited (GB) 2010-05-26 EP disclosed
EP-2176222-A1 NOVEL HERBICIDES Syngenta Limited (GB) 2010-04-21 EP disclosed
EP-2173727-A1 NOVEL HERBICIDES Syngenta Limited (GB) 2010-04-14 EP disclosed
WO-2009030450-A2 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2009-03-12 WO disclosed
WO-2009015877-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2009-02-05 WO disclosed
WO-2009000533-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040826-A1 NOVEL HERBICIDES DDT, HDHD5, DDC SMN1; SMN2 4358/4885MAPT 3907/4885RAB9A 3059/4885
US-20100298140-A1 NOVEL HERBICIDES DDT, CYP1B1, CYP1A1 SMN1; SMN2 2924/4885MAPT 3984/4885RAB9A 3091/4885
US-20100279868-A1 NOVEL HERBICIDES DDT, HPD, HSD17B1 SMN1; SMN2 4435/4885MAPT 3291/4885RAB9A 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.